Skip to main content
EXACT Therapeutics AS logo

EXACT Therapeutics AS — Investor Relations & Filings

Ticker · EXTX ISIN · NO0010852213 LEI · 2138006ZE5JAL39AGD55 OL Manufacturing
Open in API
Filings indexed 233 across all filing types
Latest filing 2023-12-01 Director's Dealing
Country NO Norway
Listing OL EXTX

About EXACT Therapeutics AS

https://www.exact-tx.com/

EXACT Therapeutics AS is a clinical-stage biopharmaceutical company developing its proprietary technology platform, Acoustic Cluster Therapy (ACT®), for targeted therapeutic enhancement. The ACT® platform uses ultrasound to amplify the effect of co-administered drugs, with a primary focus on oncology. Its biomechanical mode of action increases the local uptake of therapeutics from blood vessels into the surrounding tissue, including across the blood-brain barrier, without requiring drug reformulation. This non-invasive technology is designed to be compatible with standard ultrasound systems. The company's pipeline includes the ENACT study, a Phase 2 trial evaluating ACT® in patients with locally advanced pancreatic cancer, following the completion of the ACTIVATE Phase 1 study in patients with liver metastases.

Recent filings

Filing Released Lang Actions
EXACT Therapeutics AS: Primary insider notices
Director's Dealing Classification · 99% confidence The document text is explicitly titled "Notification of transactions by Primary Insiders and Close Associates". It details a 'Disposal' transaction involving shares by an individual identified as a Primary Insider (CFO: John Edminson) of the company. This structure perfectly matches the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The corresponding code is DIRS.
2023-12-01 English
EXACT Therapeutics AS: Primary insider notices
Director's Dealing Classification · 100% confidence The document is explicitly titled "Notification of transactions by Primary Insiders and Close Associates." It details a 'Disposal' of shares by an individual identified as a Primary Insider (Caspar Foghsgaard, Sr. VP Commercial and Business Development), including the date, price, and volume of the transaction. This directly corresponds to the definition of Director's Dealing (insider trades). Matching this content to the provided definitions: - Definition 9: Director's Dealing (Code: DIRS) - Report of personal share transactions by company directors and executives (insider trades). Therefore, the correct classification is DIRS.
2023-12-01 English
EXACT Therapeutics AS: Primary insider notices
Director's Dealing Classification · 99% confidence The document is explicitly titled "Notification of transactions by Primary Insiders and Close Associates." It details a 'Disposal' transaction involving shares by an insider named Anders Wold (Chair of the board) on a specific date (2023-11-30). This content directly corresponds to the definition of Director's Dealing, which covers reports of personal share transactions by company directors and executives.
2023-12-01 English
EXACT Therapeutics AS: Primary insider notices
Director's Dealing Classification · 99% confidence The document is explicitly titled "Notification of transactions by Primary Insiders and Close Associates." It details a 'Disposal' transaction involving shares by an individual identified as a Primary Insider (CMO) and lists the price, volume, and date of the transaction. This structure perfectly matches the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The corresponding code is DIRS.
2023-12-01 English
EXACT Therapeutics AS: Primary insider notices
Director's Dealing Classification · 99% confidence The document text is titled 'Notification of transactions by Primary Insiders and Close Associates' and details a transaction involving shares ('Share lending') by an entity ('Kvåle AS') associated with a primary insider ('Svein Kvåle'). This structure—reporting personal share transactions by directors and executives—directly matches the definition for Director's Dealing (DIRS). The document is not a full annual report (10-K), an earnings release (ER), or a general regulatory announcement (RNS), but a specific insider transaction report.
2023-12-01 English
EXACT Therapeutics AS: Primary insider notices
Director's Dealing Classification · 98% confidence The document explicitly details share subscriptions by primary insiders (CMO, CEO, Sr. VP, CFO, board members) following a private placement. It references MAR article 19 and Section 5-12 of the Norwegian Securities Trading Act, which are standard requirements for disclosing insider transactions. This directly corresponds to the definition of Director's Dealing (DIRS). Although it mentions a private placement (CAP activity), the core focus and regulatory disclosure requirement cited pertain to the insiders' resulting holdings.
2023-12-01 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.